Literature DB >> 24585742

Desensitization of myofilaments to Ca2+ as a therapeutic target for hypertrophic cardiomyopathy with mutations in thin filament proteins.

Marco L Alves1,2, Fernando A L Dias1,2, Robert D Gaffin1, Jillian N Simon1, Eric M Montminy1, Brandon J Biesiadecki1,3, Aaron C Hinken1, Chad M Warren1, Megan S Utter1, Robert T Davis1, Sadayappan Sakthivel4, Jeffrey Robbins4, David F Wieczorek5, R John Solaro1, Beata M Wolska6,1.   

Abstract

BACKGROUND: Hypertrophic cardiomyopathy (HCM) is a common genetic disorder caused mainly by mutations in sarcomeric proteins and is characterized by maladaptive myocardial hypertrophy, diastolic heart failure, increased myofilament Ca(2+) sensitivity, and high susceptibility to sudden death. We tested the following hypothesis: correction of the increased myofilament sensitivity can delay or prevent the development of the HCM phenotype. METHODS AND
RESULTS: We used an HCM mouse model with an E180G mutation in α-tropomyosin (Tm180) that demonstrates increased myofilament Ca(2+) sensitivity, severe hypertrophy, and diastolic dysfunction. To test our hypothesis, we reduced myofilament Ca(2+) sensitivity in Tm180 mice by generating a double transgenic mouse line. We crossed Tm180 mice with mice expressing a pseudophosphorylated cardiac troponin I (S23D and S24D; TnI-PP). TnI-PP mice demonstrated a reduced myofilament Ca(2+) sensitivity compared with wild-type mice. The development of pathological hypertrophy did not occur in mice expressing both Tm180 and TnI-PP. Left ventricle performance was improved in double transgenic compared with their Tm180 littermates, which express wild-type cardiac troponin I. Hearts of double transgenic mice demonstrated no changes in expression of phospholamban and sarcoplasmic reticulum Ca(2+) ATPase, increased levels of phospholamban and troponin T phosphorylation, and reduced phosphorylation of TnI compared with Tm180 mice. Moreover, expression of TnI-PP in Tm180 hearts inhibited modifications in the activity of extracellular signal-regulated kinase and zinc finger-containing transcription factor GATA in Tm180 hearts.
CONCLUSIONS: Our data strongly indicate that reduction of myofilament sensitivity to Ca(2+) and associated correction of abnormal relaxation can delay or prevent development of HCM and should be considered as a therapeutic target for HCM.

Entities:  

Keywords:  cardiac remodeling; cardiomyopathies; cardiomyopathy, hypertrophic; therapeutics

Mesh:

Substances:

Year:  2014        PMID: 24585742      PMCID: PMC4061696          DOI: 10.1161/CIRCGENETICS.113.000324

Source DB:  PubMed          Journal:  Circ Cardiovasc Genet        ISSN: 1942-3268


  55 in total

1.  Troponin I in the murine myocardium: influence on length-dependent activation and interfilament spacing.

Authors:  John P Konhilas; Thomas C Irving; Beata M Wolska; Eias E Jweied; Anne F Martin; R John Solaro; Pieter P de Tombe
Journal:  J Physiol       Date:  2003-01-24       Impact factor: 5.182

2.  Ranolazine improves cardiac diastolic dysfunction through modulation of myofilament calcium sensitivity.

Authors:  Joshua D Lovelock; Michelle M Monasky; Euy-Myoung Jeong; Harvey A Lardin; Hong Liu; Bindiya G Patel; Domenico M Taglieri; Lianzhi Gu; Praveen Kumar; Narayan Pokhrel; Dewan Zeng; Luiz Belardinelli; Dan Sorescu; R John Solaro; Samuel C Dudley
Journal:  Circ Res       Date:  2012-02-16       Impact factor: 17.367

3.  Expression of slow skeletal troponin I in hearts of phospholamban knockout mice alters the relaxant effect of beta-adrenergic stimulation.

Authors:  Beata M Wolska; Grace M Arteaga; James R Peña; Grzegorz Nowak; Ronald M Phillips; Shalini Sahai; Pieter P de Tombe; Anne F Martin; Evangelia G Kranias; R John Solaro
Journal:  Circ Res       Date:  2002-05-03       Impact factor: 17.367

4.  Phosphorylation of troponin I by protein kinase A accelerates relaxation and crossbridge cycle kinetics in mouse ventricular muscle.

Authors:  J C Kentish; D T McCloskey; J Layland; S Palmer; J M Leiden; A F Martin; R J Solaro
Journal:  Circ Res       Date:  2001-05-25       Impact factor: 17.367

5.  Altered hemodynamics in transgenic mice harboring mutant tropomyosin linked to hypertrophic cardiomyopathy.

Authors:  C C Evans; J R Pena; R M Phillips; M Muthuchamy; D F Wieczorek; R J Solaro; B M Wolska
Journal:  Am J Physiol Heart Circ Physiol       Date:  2000-11       Impact factor: 4.733

6.  Binding of levosimendan, a calcium sensitizer, to cardiac troponin C.

Authors:  T Sorsa; S Heikkinen; M B Abbott; E Abusamhadneh; T Laakso; C Tilgmann; R Serimaa; A Annila; P R Rosevear; T Drakenberg; P Pollesello; I Kilpelainen
Journal:  J Biol Chem       Date:  2000-12-11       Impact factor: 5.157

7.  Phosphorylation of troponin I controls cardiac twitch dynamics: evidence from phosphorylation site mutants expressed on a troponin I-null background in mice.

Authors:  YeQing Pi; Kara R Kemnitz; Dahua Zhang; Evangelia G Kranias; Jeffery W Walker
Journal:  Circ Res       Date:  2002-04-05       Impact factor: 17.367

8.  A familial hypertrophic cardiomyopathy alpha-tropomyosin mutation causes severe cardiac hypertrophy and death in mice.

Authors:  R Prabhakar; G P Boivin; I L Grupp; B Hoit; G Arteaga; R J Solaro; D F Wieczorek
Journal:  J Mol Cell Cardiol       Date:  2001-10       Impact factor: 5.000

9.  Increased Ca2+-sensitivity of the contractile apparatus in end-stage human heart failure results from altered phosphorylation of contractile proteins.

Authors:  J van der Velden; Z Papp; R Zaremba; N M Boontje; J W de Jong; V J Owen; P B J Burton; P Goldmann; K Jaquet; G J M Stienen
Journal:  Cardiovasc Res       Date:  2003-01       Impact factor: 10.787

10.  Troponin I phosphorylation plays an important role in the relaxant effect of beta-adrenergic stimulation in mouse hearts.

Authors:  James R Peña; Beata M Wolska
Journal:  Cardiovasc Res       Date:  2004-03-01       Impact factor: 10.787

View more
  39 in total

Review 1.  The genetic basis of hypertrophic cardiomyopathy in cats and humans.

Authors:  Mark D Kittleson; Kathryn M Meurs; Samantha P Harris
Journal:  J Vet Cardiol       Date:  2015-12       Impact factor: 1.701

Review 2.  Phenotyping cardiomyopathy in adult zebrafish.

Authors:  Alexey V Dvornikov; Pieter P de Tombe; Xiaolei Xu
Journal:  Prog Biophys Mol Biol       Date:  2018-05-30       Impact factor: 3.667

Review 3.  Myocardial energy depletion and dynamic systolic dysfunction in hypertrophic cardiomyopathy.

Authors:  Julian O M Ormerod; Michael P Frenneaux; Mark V Sherrid
Journal:  Nat Rev Cardiol       Date:  2016-07-14       Impact factor: 32.419

4.  N-acetylcysteine reverses diastolic dysfunction and hypertrophy in familial hypertrophic cardiomyopathy.

Authors:  Tanganyika Wilder; David M Ryba; David F Wieczorek; Beata M Wolska; R John Solaro
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-10-02       Impact factor: 4.733

5.  Knockout of p21-activated kinase-1 attenuates exercise-induced cardiac remodelling through altered calcineurin signalling.

Authors:  Robert T Davis; Jillian N Simon; Megan Utter; Paul Mungai; Manuel G Alvarez; Shamim A K Chowdhury; Ahlke Heydemann; Yunbo Ke; Beata M Wolska; R John Solaro
Journal:  Cardiovasc Res       Date:  2015-10-12       Impact factor: 10.787

6.  Pathogenic troponin T mutants with opposing effects on myofilament Ca2+ sensitivity attenuate cardiomyopathy phenotypes in mice.

Authors:  Karissa M Dieseldorff Jones; Yeojung Koh; Rebecca S Weller; Rajdeep S Turna; Ferhaan Ahmad; Sabine Huke; Björn C Knollmann; Jose Renato Pinto; Hyun Seok Hwang
Journal:  Arch Biochem Biophys       Date:  2018-11-13       Impact factor: 4.013

7.  Peroxisome proliferator-activated receptor-α expression induces alterations in cardiac myofilaments in a pressure-overload model of hypertrophy.

Authors:  Chehade N Karam; Chad M Warren; Marcus Henze; Natasha H Banke; E Douglas Lewandowski; R John Solaro
Journal:  Am J Physiol Heart Circ Physiol       Date:  2017-01-27       Impact factor: 4.733

8.  Hypertrophic Cardiomyopathy: A Vicious Cycle Triggered by Sarcomere Mutations and Secondary Disease Hits.

Authors:  Paul J M Wijnker; Vasco Sequeira; Diederik W D Kuster; Jolanda van der Velden
Journal:  Antioxid Redox Signal       Date:  2018-04-11       Impact factor: 8.401

Review 9.  Strategies for targeting the cardiac sarcomere: avenues for novel drug discovery.

Authors:  Joshua B Holmes; Chang Yoon Doh; Ranganath Mamidi; Jiayang Li; Julian E Stelzer
Journal:  Expert Opin Drug Discov       Date:  2020-02-18       Impact factor: 6.098

10.  Diastolic dysfunction and cardiac troponin I decrease in aging hearts.

Authors:  B Pan; Z W Xu; Y Xu; L J Liu; J Zhu; X Wang; C Nan; Z Zhang; W Shen; X P Huang; J Tian
Journal:  Arch Biochem Biophys       Date:  2016-05-13       Impact factor: 4.013

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.